Inhibition of Platelet Function by the Endothelium

Platelets, Third Edition

Volumn , Issue , 2012, Pages 313-342

  Beaulieu, Lea M ^a   Freedman, Jane E ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84947258572     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387837-3.00017-1     Document Type: Chapter

References (469)

1. A.J. Marcus, L.B. Safier, W.E. Kaminski, N. Islam, K.A. Hajjar, E. Jendraschak, et al. (1995) Principles of thromboregulation: control of platelet reactivity in vascular disease. Adv Prostaglandin Thromboxane Leukot Res 23 413-418.
2. A.J. Marcus and L.B. Safier (1993) Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. Faseb J 7(6), 516-522.
3. A.J. Marcus, M.J. Broekman, J.H. Drosopoulos, N. Islam, D.J. Pinsky, C. Sesti, et al. (2003) Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1). J Thromb Haemost 1(12), 2497-2509.
4. A.J. Marcus, M.J. Broekman, J.H. Drosopoulos, K.E. Olson, N. Islam, D.J. Pinsky, et al. (2005) Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost 31(2), 234-246.
5. R.F. Furchgott and J.V. Zawadzki (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288(5789), 373-376.
6. J.S. Stamler, D.J. Singel and J. Loscalzo (1992) Biochemistry of nitric oxide and its redox-activated forms. Science 258(5090), 1898-1902.
7. G. Walford and J. Loscalzo (2003) Nitric oxide in vascular biology. J Thromb Haemost 1(10), 2112-2118.
8. R. Radi, J.S. Beckman, K.M. Bush and B.A. Freeman (1991) Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem 266(7), 4244-4250.
9. G. Rubanyi and P. Vanhoutte (1986) Superoxide anions and hyperoxia inactivate endothlium-derived relaxing factor. Am J Physiol 250(5, Pt. 2), H882-H887.
10. G.M. Rubanyi and P.M. Vanhoutte (1986) Oxygen-derived free radicals, endothelium, and responsiveness of vascular smooth muscle. Am J Physiol 250(5, Pt. 2), H815-H821.
11. Z. Lacza, J.A. Snipes, J. Zhang, E.M. Horvath, J.P. Figueroa, C. Szabo, et al. (2003) Mitochondrial nitric oxide synthase is not eNOS, nNOS or iNOS. Free Radic Biol Med 35(10), 1217-1228.
12. M.C. Carreras, M.C. Franco, J.G. Peralta and J.J. Poderoso (2004) Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease. Mol Aspects Med 25(1–2), 125-139.
13. V. Haynes, S. Elfering, N. Traaseth and C. Giulivi (2004) Mitochondrial nitric-oxide synthase: enzyme expression, characterization, and regulation. J Bioenerg Biomembr 36(4), 341-346.
14. P. Ghafourifar and E. Cadenas (2005) Mitochondrial nitric oxide synthase. Trends Pharmacol Sci 26(4), 190-195.
15. J.S. Pollock, U. Forstermann, J.A. Mitchell, T.D. Warner, H.H. Schmidt, M. Nakane, et al. (1991) Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 88(23), 10480-10484.
16. C. Nathan (1992) Nitric oxide as a secretory product of mammalian cells. Faseb J 6(12), 3051-3064.
17. T. Michel and O. Feron (1997) Nitric oxide synthases: Which, where, how, and why? J Clin Invest 100(9), 2146-2152.
18. P.W. Shaul, A.J. North, L.C. Wu, L.B. Wells, T.S. Brannon, K.S. Lau, et al. (1994) Endothelial nitric oxide synthase is expressed in cultured human bronchiolar epithelium. J Clin Invest 94(6), 2231-2236.
19. Z. German, K.L. Chambliss, M.C. Pace, U.A. Arnet, C.J. Lowenstein and P.W. Shaul (2000) Molecular basis of cell-specific endothelial nitric-oxide synthase expression in airway epithelium. J Biol Chem 275(11), 8183-8189.
20. J.L. Mehta, L.Y. Chen, B.C. Kone, P. Mehta and P. Turner (1995) Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med 125 370-377.
21. K. Sase and T. Michel (1995) Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci 57 2049-2055.
22. Q. Zhou, G. Hellermann and L. Solomonson (1995) Nitric oxide release from resting human platelets. Thromb Res 77 87-96.
23. W.K. Alderton, C.E. Cooper and R.G. Knowles (2001) Nitric oxide synthases: structure, function and inhibition. Biochem J 357(Pt. 3), 593-615.
24. C.S. Raman, H. Li, P. Martasek, V. Kral, B.S. Masters and T.L. Poulos (1998) Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center. Cell 95(7), 939-950.
25. T.O. Fischmann, A. Hruza, X.D. Niu, J.D. Fossetta, C.A. Lunn, E. Dolphin, et al. (1999) Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat Struct Biol 6(3), 233-242.
26. B.R. Crane, R.J. Rosenfeld, A.S. Arvai, D.K. Ghosh, S. Ghosh, J.A. Tainer, et al. (1999) N-terminal domain swapping and metal ion binding in nitric oxide synthase dimerization. Embo J 18(22), 6271-6281.
27. M.A. Marletta, P.S. Yoon, R. Iyengar, C.D. Leaf and J.S. Wishnok (1988) Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry 27(24), 8706-8711.
28. S. Lamas, P.A. Marsden, G.K. Li, P. Tempst and T. Michel (1992) Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci USA 89(14), 6348-6352.
29. L.J. Robinson and T. Michel (1995) Mutagenesis of palmitoylation sites in endothelial nitric oxide synthase identifies a novel motif for dual acylation and subcellular targeting. Proc Natl Acad Sci USA 92(25), 11776-11780.
30. P.W. Shaul (2002) Regulation of endothelial nitric oxide synthase: Location, location, location. Annu Rev Physiol 64 749-774.
31. O. Feron, L. Belhassen, L. Kobzik, T.W. Smith, R.A. Kelly and T. Michel (1996) Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 271(37), 22810-22814.
32. P.A. Conrad, E.J. Smart, Y.S. Ying, R.G. Anderson and G.S. Bloom (1995) Caveolin cycles between plasma membrane caveolae and the Golgi complex by microtubule-dependent and microtubule-independent steps. J Cell Biol 131(6, Pt. 1), 1421-1433.
33. P.W. Shaul, E.J. Smart, L.J. Robinson, Z. German, I.S. Yuhanna, Y. Ying, et al. (1996) Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae. J Biol Chem 271(11), 6518-6522.
34. M. Bucci, J.P. Gratton, R.D. Rudic, L. Acevedo, F. Roviezzo, G. Cirino, et al. (2000) In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 6(12), 1362-1367.
35. I. Fleming and R. Busse (2003) Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 284(1), R1-12.
36. G.M. Rubanyi, J.C. Romero and P.M. Vanhoutte (1986) Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 250(6, Pt. 2), H1145-H1149.
37. D. Fulton, J.P. Gratton, T.J. McCabe, J. Fontana, Y. Fujio, K. Walsh, et al. (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399(6736), 597-601.
38. S. Dimmeler, I. Fleming, B. Fisslthaler, C. Hermann, R. Busse and A.M. Zeiher (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399(6736), 601-605.
39. R.L. Ross, M.R. Serock and R.A. Khalil (2008) Experimental benefits of sex hormones on vascular function and the outcome of hormone therapy in cardiovascular disease. Curr Cardiol Rev 4(4), 309-322.
40. M. Zerr-Fouineau, M. Jourdain, C. Boesch, M. Hecker, C. Bronner and V.B. Schini-Kerth (2009) Certain progestins prevent the enhancing effect of 17beta-estradiol on NO-mediated inhibition of platelet aggregation by endothelial cells. Arterioscler Thromb Vasc Biol 29(4), 586-593.
41. T. Simoncini, A. Caruso, S. Garibaldi, X.D. Fu, MS Giretti, C. Baldacci, et al. (2006) Activation of nitric oxide synthesis in human endothelial cells using nomegestrol acetate. Obstet Gynecol 108(4), 969-978.
42. G. Gonzalez, N. Alvarado-Vasquez, G.J. Fernandez, D. Cruz-Robles, L. Del Valle, E. Pinzon, et al. (2010) The antithrombotic effect of the aminoestrogen prolame (N-(3-hydroxy-1,3,5(10)-estratrien-17B-YL)-3-hydroxypropylamine) is linked to an increase in nitric oxide production by platelets and endothelial cells. Atherosclerosis 208(1), 62-68.
43. A. Papapetropoulos, R.D. Rudic and W.C. Sessa (1999) Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc Res 43(3), 509-520.
44. P.J. Andrew and B. Mayer (1999) Enzymatic function of nitric oxide synthases. Cardiovasc Res 43(3), 521-531.
45. R. Govers and T.J. Rabelink (2001) Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 280(2), F193-F206.
46. J. Beckman, T. Beckman, J. Chen, P. Marshall and B. Freeman (1990) Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87 1620-1624.
47. R. Radi, J.S. Beckman, K.M. Bush and B.A. Freeman (1991) Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 288(2), 481-487.
48. L.J. Ignarro (1989) Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 65(1), 1-21.
49. J.C. de Graaf, J.D. Banga, S. Moncada, R.M. Palmer, P.G. de Groot and J.J. Sixma (1992) Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 85 2284-2290.
50. H. Azuma, M. Ishikawa and S. Sekizaki (1986) Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 88(2), 411-415.
51. M.J. Broekman, A.M. Eiroa and A.J. Marcus (1991) Inhibition of human platelet reactivity by endothelium-derived relaxing factor from human umbilical vein endothelial cells in suspension: blockade of aggregation and secretion by an aspirin-insensitive mechanism. Blood 78(4), 1033-1040.
52. J. Stamler, M.E. Mendelsohn, P. Amarante, D. Smick, N. Andon, P.F. Davies, et al. (1989) N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res 65 789-795.
53. J.P. Cooke, J. Stamler, N. Andon, P.F. Davies, G. McKinley and J. Loscalzo (1990) Flow stimulates endothelial cells to release a nitrovasodilator that is potentiated by reduced thiol. Am J Physiol 259(3, Pt. 2), H804-H812.
54. T.C. Bellamy and J. Garthwaite (2002) The receptor-like properties of nitric oxide-activated soluble guanylyl cyclase in intact cells. Mol Cell Biochem 230(1–2), 165-176.
55. F. Murad, C.K. Mittal, W.P. Arnold, S. Katsuki and H. Kimura (1978) Guanylate cyclase: activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin. Adv Cyclic Nucleotide Res 9 145-158.
56. T.D. Warner (1996) Influence of endothelial mediators on the vascular smooth muscle and circulating platelets and blood cells. Int Angiol 15(2), 93-99.
57. J.A. Beavo and L.L. Brunton (2002) Cyclic nucleotide research—still expanding after half a century. Nat Rev Mol Cell Biol 3(9), 710-718.
58. K.A. Hanafy, J.S. Krumenacker and F. Murad (2001) NO, nitrotyrosine, and cyclic GMP in signal transduction. Med Sci Monit 7(4), 801-819.
59. R. Feil, S.M. Lohmann, H. de Jonge, U. Walter and F. Hofmann (2003) Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res 93(10), 907-916.
60. M. Moro, R. Russel, S. Cellek, I. Lizasoain, Y. Su, V. Darley-Usman, et al. (1996) cGMP mediates the vascular and platelet action of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cylase. Proc Natl Acad Sci USA 93 1480-1485.
61. G.H. Rao, S. Krishnamurthi, L. Raij and J.G. White (1990) Influence of nitric oxide on agonist-mediated calcium mobilization in platelets. Biochem Med Metab Biol 43(3), 271-275.
62. U. Walter, J. Geiger, C. Haffner, T. Markert, C. Nehls, R.E. Silber, et al. (1995) Platelet-vessel wall interactions, focal adhesions, and the mechanism of action of endothelial factors. Agents Actions Suppl 45 255-268.
63. R.C. Jin, B. Voetsch and J. Loscalzo (2005) Endogenous mechanisms of inhibition of platelet function. Microcirculation 12(3), 247-258.
64. A.D. Michelson, S.E. Benoit, M.I. Furman, W.L. Breckwoldt, M.J. Rohrer, M.R. Barnard, et al. (1996) Effects of nitric oxide/endothelium-derived relaxing factor on platelet surface glycoproteins. Am J Physiol 270(5, Pt. 2), H1640-H1648.
65. M.E. Mendelsohn, S. O’Neill, D. George and J. Loscalzo (1990) Inhibition of fibrinogen binding to human platelets by S-nitroso-N-acetylcysteine. J Biol Chem 265(31), 19028-19034.
66. A. Pigazzi, S. Heydrick, F. Folli, S. Benoit, A. Michelson and J. Loscalzo (1999) Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets. J Biol Chem 274(20), 14368-14375.
67. K. Horstrup, B. Jablonka, P. Honig-Liedl, M. Just, K. Kochsiek and U. Walter (1994) Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem 225(1), 21-27.
68. M. Radomski and S. Moncada (1993) Regulation of vascular homeostasis by nitric oxide. Thrombosis Haemostasis 70 36-41.
69. G.R. Wang, Y. Zhu, P.V. Halushka, T.M. Lincoln and M.E. Mendelsohn (1998) Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci USA 95(9), 4888-4893.
70. T. Murohara, S. Parkinson, S. Waldman and A. Lefer (1995) Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets. Arterioscler Thromb Vasc Biol 15 2068-2075.
71. J.S. Stamler, D.I. Simon, J.A. Osborne, M.E. Mullins, O. Jaraki, T. Michel, et al. (1992) S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA 89(1), 444-448.
72. J.S. Stamler, D.I. Simon, O. Jaraki, J.A. Osborne, S. Francis, M. Mullins, et al. (1992) S-nitrosylation of tissue-type plasminogen activator confers vasodilatory and antiplatelet properties on the enzyme. Proc Natl Acad Sci USA 89(17), 8087-8091.
73. J.S. Scharfstein, J.F. Keaney Jr, A. Slivka, G.N. Welch, J.A. Vita, J.S. Stamler, et al. (1994) In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest 94(4), 1432-1439.
74. Z. Liu, M.A. Rudd, J.E. Freedman and J. Loscalzo (1998) S-Transnitrosation reactions are involved in the metabolic fate and biological actions of nitric oxide. J Pharmacol Exp Ther 284(2), 526-534.
75. A.J. de Belder, R. MacAllister, M.W. Radomski, S. Moncada and P.J. Vallance (1994) Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc Res 28(5), 691-694.
76. M.S. Crane, R. Ollosson, K.P. Moore, A.G. Rossi and I.L. Megson (2002) Novel role for low molecular weight plasma thiols in nitric oxide-mediated control of platelet function. J Biol Chem 277(49), 46858-46863.
77. M.S. Crane, A.G. Rossi and I.L. Megson (2005) A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations. Br J Pharmacol 144(6), 849-859.
78. T. Malinski, M.W. Radomski, Z. Taha and S. Moncada (1993) Direct electrochemical measurement of nitric oxide released from human platelets. Biochem Biophys Res Commun 194 960-965.
79. M.W. Radomski, R.M.J. Palmer and S. Moncada (1990) An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 87 5193-5197.
80. J.E. Freedman, J. Loscalzo, M.R. Barnard, C. Alpert, J.F. Keaney Jr and A. Michelson (1997) Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 100 350-356.
81. J. Freedman, R. Sauter, B. Battinelli, A. Ault, C. Knowles, P. Huang, et al. (1999) Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOS3 gene. Circ Res 84 1416-1421.
82. B. Patel, M. Sharifi, A.D. Milward, N.G. Oberprieler, J.M. Gibbins, S. Parkin, et al. (2006) Platelet nitric oxide synthase is activated by tyrosine dephosphorylation: possible role for SHP-1 phosphatase. J Thromb Haemost 4(11), 2423-2432.
83. P. Gresele, P. Pignatelli, G. Guglielmini, R. Carnevale, A.M. Mezzasoma, A. Ghiselli, et al. (2008) Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J Nutr 138(9), 1602-1608.
84. G.J. Wu, J.J. Lee, D.S. Chou, T. Jayakumar, G. Hsiao, W.F. Chen, et al. (2010) Inhibitory signaling of 17beta-estradiol in platelet activation: the pivotal role of cyclic AMP-mediated nitric oxide synthase activation. Eur J Pharmacol 649(1–3), 140-149.
85. K. Takeuchi, H. Watanabe, Q.K. Tran, M. Ozeki, D. Sumi, T. Hayashi, et al. (2004) Nitric oxide: inhibitory effects on endothelial cell calcium signaling, prostaglandin I2 production and nitric oxide synthase expression. Cardiovasc Res 62(1), 194-201.
86. J. Loscalzo (2001) Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 88(8), 756-762.
87. F. Krotz, H.Y. Sohn and U. Pohl (2004) Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol 24(11), 1988-1996.
88. A. Friebe and D. Koesling (2003) Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 93(2), 96-105.
89. D. Salvemini, W. Radziszewski, V. Mollace, A. Moore, D. Willoughby and J. Vane (1991) Diphenylene iodonium, an inhibitor of free radical formation, inhibits platelet aggregation. Eur J Pharmacol 199(1), 15-18.
90. S. Chlopicki, R. Olszanecki, M. Janiszewski, F.R. Laurindo, T. Panz and J. Miedzobrodzki (2004) Functional role of NADPH oxidase in activation of platelets. Antioxid Redox Signal 6(4), 691-698.
91. P. Clutton, A. Miermont and J.E. Freedman (2004) Regulation of endogenous reactive oxygen species in platelets can reverse aggregation. Arterioscler Thromb Vasc Biol 24(1), 187-192.
92. B. Jahn and G.M. Hansch (1990) Oxygen radical generation in human platelets: dependence on 12-lipoxygenase activity and on the glutathione cycle. Int Arch Allergy Appl Immunol 93(1), 73-79.
93. J.E. Freedman, B. Frei, G.N. Welch and J. Loscalzo (1995) Glutathione peroxidase potentiates the inhibition of platelet function by S-nitrosothiols. J Clin Invest 96(1), 394-400.
94. J. Igarashi, M. Miyoshi, T. Hashimoto, Y. Kubota and H. Kosaka (2007) Hydrogen peroxide induces S1P1 receptors and sensitizes vascular endothelial cells to sphingosine 1-phosphate, a platelet-derived lipid mediator. Am J Physiol Cell Physiol 292(2), C740-C748.
95. L.J. Ignarro and C. Napoli (2004) Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis. Curr Atheroscler Rep 6(4), 281-287.
96. S. Kawashima and M. Yokoyama (2004) Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 24(6), 998-1005.
97. R.A. Cohen (1995) The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis 38(2), 105-128.
98. D.G. Harrison (1994) Endothelial dysfunction in atherosclerosis. Basic Res Cardiol 89(Suppl. 1), 87-102.
99. N.A. Flavahan (1992) Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation 85(5), 1927-1938.
100. R. Khan, L.A. Kirschenbaum, C. LaRow, G. Berna, K. Griffin and M.E. Astiz (2010) Augmentation of platelet and endothelial cell eNOS activity decreases sepsis-related neutrophil-endothelial cell interactions. Shock 33(3), 242-246.
101. P.L. Huang, Z. Huang, H. Mashimo, K.D. Bloch, M.A. Moskowitz, J.A. Bevan, et al. (1995) Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377 239-242.
102. M.D. Iafrati, O. Vitseva, K. Tanriverdi, P. Blair, S. Rex, S. Chakrabarti, et al. (2005) Compensatory mechanisms influence hemostasis in setting of eNOS deficiency. Am J Physiol Heart Circ Physiol 288(4), H1627-H1632.
103. X. Dai and J.E. Faber (2010) Endothelial nitric oxide synthase deficiency causes collateral vessel rarefaction and impairs activation of a cell cycle gene network during arteriogenesis. Circ Res 106(12), 1870-1881.
104. S.P. Jones, J.J. Greer, R. van Haperen, D.J. Duncker, R. de Crom and D.J. Lefer (2003) Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci USA 100(8), 4891-4896.
105. S.P. Jones, J.J. Greer, A.K. Kakkar, P.D. Ware, R.H. Turnage, M. Hicks, et al. (2004) Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 286(1), H276-H282.
106. S. Kawashima, T. Yamashita, M. Ozaki, Y. Ohashi, H. Azumi, N. Inoue, et al. (2001) Endothelial NO synthase overexpression inhibits lesion formation in mouse model of vascular remodeling. Arterioscler Thromb Vasc Biol 21(2), 201-207.
107. M. Ozaki, S. Kawashima, T. Yamashita, T. Hirase, M. Namiki, N. Inoue, et al. (2002) Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 110(3), 331-340.
108. J.A. Vita, C.B. Treasure, E.G. Nabel, J.M. McLenachan, R. Fish, A.C. Yeung, et al. (1990) Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81 491-497.
109. D.J. Fitzgerald, L. Roy, F. Catella and A. FitzGerald (1986) Platelet activation in unstable coronary disease. N Engl J Med 315 983-989.
110. J.E. Freedman, B. Ting, B. Hankin, J. Loscalzo, J.F.J. Keaney and J.A. Vita (1998) Impaired platelet production of nitric oxide in patients with unstable angina. Circulation 98 1481-1486.
111. J.E. Freedman, B. Ting, B. Hankin, J. Loscalzo, J.F. Keaney Jr and J.A. Vita (1998) Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 98(15), 1481-1486.
112. C. Bossaller, G.B. Habib, H. Yamamoto, C. Williams, S. Wells and P.D. Henry (1986) Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5'-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest 79(79), 170-174.
113. C.D. Cool, J.S. Stewart, P. Werahera, G.J. Miller, R.L. Williams, N.F. Voelkel, et al. (1999) Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155(2), 411-419.
114. A. Giaid and D. Saleh (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333(4), 214-221.
115. N. Stagliano, W. Zhao, R. Prado, M. Dewanjee, M. Ginsberg and W. Dietrich (1997) The effect of nitric oxide synthase inhibition on acute platelet accumulation and hemodynamic depression in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 17 1182-1190.
116. J.E. Freedman, J. Loscalzo, S.E. Benoit, C.R. Valeri, M.R. Barnard and A.D. Michelson (1996) Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest 97 979-987.
117. G. Goumas, C. Tentolouris, D. Tousoulis, C. Stefanadis and P. Toutouzas (2001) Therapeutic modification of the L-arginine-eNOS pathway in cardiovascular diseases. Atherosclerosis 154(2), 255-267.
118. J.D. Folts, J. Stamler and J. Loscalzo (1991) Intravenous nitroglycerin infusion inhibits cyclic blood flow responses caused by periodic platelet thrombus formation in stenosed canine coronary arteries. Circulation 83(6), 2122-2127.
119. Z. Nong, M. Hoylaerts, N. Van Pelt, D. Collen and S. Janssens (1997) Nitric oxide inhalation inhibits platelet aggregation and platelet-mediated pulmonary thrombosis in rats. Circ Res 81(5), 865-869.
120. R.C. Candipan, B.Y. Wang, R. Buitrago, P.S. Tsao and J.P. Cooke (1996) Regression or progression. Dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol 16(1), 44-50.
121. W. Aji, S. Ravalli, M. Szabolcs, X.C. Jiang, R.R. Sciacca, R.E. Michler, et al. (1997) L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation 95(2), 430-437.
122. M. Adams, C. Forsyth, W. Jessup, J. Robinson and D. Celermajer (1995) Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll Cardiol 26 1054-1061.
123. D.I. Simon, J.S. Stamler, E. Loh, J. Loscalzo, S.A. Frances and M.A. Creager (1995) Effect of nitric oxide synthase inhibition on bleeding time in humans. J Cardiovasc Pharm 26 339-342.
124. A.A. Quyyumi, N. Dakak, N.P. Andrews, S. Husain, S. Arora, D.M. Gilligan, et al. (1995) Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 95(4), 1747-1755.
125. G.I. Boger, T.K. Rudolph, R. Maas, E. Schwedhelm, E. Dumbadze, A. Bierend, et al. (2007) Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin: effect of combination with oral L-arginine. J Am Coll Cardiol 49(23), 2274-2282.
126. M.F. McCarty (2007) Gamma-tocopherol may promote effective no synthase function by protecting tetrahydrobiopterin from peroxynitrite. Med Hypotheses 69(6), 1367-1370.
127. C.K. Armah, K.G. Jackson, I. Doman, L. James, F. Cheghani and A.M. Minihane (2008) Fish oil fatty acids improve postprandial vascular reactivity in healthy men. Clin Sci (Lond) 114(11), 679-686.
128. A. Koltermann, A. Hartkorn, E. Koch, R. Furst, A.M. Vollmar and S. Zahler (2007) Ginkgo biloba extract EGb 761 increases endothelial nitric oxide production in vitro and in vivo. Cell Mol Life Sci 64(13), 1715-1722.
129. S.J. Moat, A. Madhavan, S.Y. Taylor, N. Payne, R.H. Allen, S.P. Stabler, et al. (2006) High- but not low-dose folic acid improves endothelial function in coronary artery disease. Eur J Clin Invest 36(12), 850-859.
130. S. Sakakibara, R. Murakami, M. Takahashi, T. Fushimi, T. Murohara, M. Kishi, et al. (2010) Vinegar intake enhances flow-mediated vasodilatation via upregulation of endothelial nitric oxide synthase activity. Biosci Biotechnol Biochem 74(5), 1055-1061.
131. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. 1997;349(9063):1429–1435.
132. N.S. Kleiman, A.M. Lincoff, E.M. Ohman and R.A. Harrington (1998) Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. Am Heart J 136(4, Pt. 2 Su.), S32-S42.
133. T. Heitzer, I. Ollmann, K. Koke, T. Meinertz and T. Munzel (2003) Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease. Circulation 108(5), 536-541.
134. D. Keh, M. Gerlach, I. Kurer, S. Seiler, T. Kerner, K.J. Falke, et al. (1996) The effects of nitric oxide (NO) on platelet membrane receptor expression during activation with human alpha-thrombin. Blood Coagul Fibrinolysis 7(6), 615-624.
135. M.J. Quinn, T.V. Byzova, J. Qin, E.J. Topol and E.F. Plow (2003) Integrin alphaIIbbeta3 and its antagonism. Arterioscler Thromb Vasc Biol 23(6), 945-952.
136. M.J. Quinn, E.F. Plow and E.J. Topol (2002) Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 106(3), 379-385.
137. L. Comini, T. Bachetti, A. Cargnoni, D. Bastianon, G.L. Gitti, C. Ceconi, et al. (2007) Therapeutic modulation of the nitric oxide: all ACE inhibitors are not equivalent. Pharmacol Res 56(1), 42-48.
138. H. Morawietz, S. Rohrbach, U. Rueckschloss, E. Schellenberger, K. Hakim, H.R. Zerkowski, et al. (2006) Increased cardiac endothelial nitric oxide synthase expression in patients taking angiotensin-converting enzyme inhibitor therapy. Eur J Clin Invest 36(10), 705-712.
139. P. Keul, M. Tolle, S. Lucke, K. von Wnuck Lipinski, G. Heusch, M. Schuchardt, et al. (2007) The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27(3), 607-613.
140. P. Li, R. Shibata, S. Maruyama, M. Kondo, K. Ohashi, N. Ouchi, et al. (2010) Fenofibrate promotes ischemia-induced revascularization through the adiponectin-dependent pathway. Am J Physiol Endocrinol Metab 299(4), E560-E566.
141. C.J. O'Donnell, M.G. Larson, D. Feng, P.A. Sutherland, K. Lindpaintner, R.H. Myers, et al. (2001) Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 103(25), 3051-3056.
142. T. Tsukada, K. Yokoyama, T. Arai, F. Takemoto, S. Hara, A. Yamada, et al. (1998) Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 245(1), 190-193.
143. Y. Yoon, J. Song, S.H. Hong and J.Q. Kim (2000) Plasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. Clin Chem 46(10), 1626-1630.
144. J.P. Casas, L.E. Bautista, S.E. Humphries and A.D. Hingorani (2004) Endothelial nitric oxide synthase genotype and ischemic heart disease: Meta-analysis of 26 studies involving 23028 subjects. Circulation 109(11), 1359-1365.
145. S. Ichihara, Y. Yamada, T. Fujimura, N. Nakashima and M. Yokota (1998) Association of a polymorphism of the endothelial constitutive nitric oxide synthase gene with myocardial infarction in the Japanese population. Am J Cardiol 81(1), 83-86.
146. H.H. Sigusch, R. Surber, M.H. Lehmann, S. Surber, J. Weber, A. Henke, et al. (2000) Lack of association between 27-bp repeat polymorphism in intron 4 of the endothelial nitric oxide synthase gene and the risk of coronary artery disease. Scand J Clin Lab Invest 60(3), 229-235.
147. T.A. Kunnas, E. Ilveskoski, T. Niskakangas, P. Laippala, O.A. Kajander, J. Mikkelsson, et al. (2002) Association of the endothelial nitric oxide synthase gene polymorphism with risk of coronary artery disease and myocardial infarction in middle-aged men. J Mol Med 80(9), 605-609.
148. I.J. Kim, J. Bae, S.W. Lim, D.H. Cha, H.J. Cho, S. Kim, et al. (2007) Influence of endothelial nitric oxide synthase gene polymorphisms (-786T>C, 4a4b, 894G>T) in Korean patients with coronary artery disease. Thromb Res 119(5), 579-585.
149. B. Morray, I. Goldenberg, A.J. Moss, W. Zareba, D. Ryan, S. McNitt, et al. (2007) Polymorphisms in the paraoxonase and endothelial nitric oxide synthase genes and the risk of early-onset myocardial infarction. Am J Cardiol 99(8), 1100-1105.
150. H.M. Colhoun, P.M. McKeigue and G. Davey Smith (2003) Problems of reporting genetic associations with complex outcomes. Lancet 361(9360), 865-872.
151. J.E. Tanus-Santos, M. Desai and D.A. Flockhart (2001) Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 11(8), 719-725.
152. J. Song, O.J. Kim, H.S. Kim, S.J. Bae, S.P. Hong, D. Oh, et al. (2010) Endothelial nitric oxide synthase gene polymorphisms and the risk of silent brain infarction. Int J Mol Med 25(5), 819-823.
153. T.G. Kim, N.K. Kim, M.J. Baek, R. Huh, S.S. Chung, J.U. Choi, et al. (2011) The relationships between endothelial nitric oxide synthase polymorphisms and the formation of intracranial aneurysms in the Korean population. Neurosurg Focus 30(6), E23.
154. L. Koshy, H.V. Easwer, N.V. Neetha, C. Natarajan, R.N. Bhattacharya and M. Banerjee (2008) Role of endothelial nitric oxide synthase gene polymorphisms in predicting aneurysmal subarachnoid hemorrhage in South Indian patients. Dis Markers 24(6), 333-339.
155. N.U. Ko, P. Rajendran, H. Kim, M. Rutkowski, L. Pawlikowska, P.Y. Kwok, et al. (2008) Endothelial nitric oxide synthase polymorphism (-786T->C) and increased risk of angiographic vasospasm after aneurysmal subarachnoid hemorrhage. Stroke 39(4), 1103-1108.
156. S. Saidi, S.G. Mallat, W.Y. Almawi and T. Mahjoub (2010) Endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786T>C gene polymorphisms and the risk of ischemic stroke. Acta Neurol Scand 121(2), 114-119.
157. J. Cheng, J. Liu, X. Li, L. Yu, J. Peng, R. Zhang, et al. (2008) Effect of polymorphisms of endothelial nitric oxide synthase on ischemic stroke: a case-control study in a Chinese population. Clin Chim Acta 392(1–2), 46-51.
158. M. Yemisci, I. Sinici, H.A. Ozkara, M. Hayran, H. Ay, B. Celtikci, et al. (2009) Protective role of 27bp repeat polymorphism in intron 4 of eNOS gene in lacunar infarction. Free Radic Res 43(3), 272-279.
159. D.C. Souza-Costa, V.A. Belo, P.S. Silva, J.T. Sertorio, I.F. Metzger, C.M. Lanna, et al. (2011) eNOS haplotype associated with hypertension in obese children and adolescents. Int J Obes (Lond) 35(3), 387-392.
160. V.C. Sandrim, A.C. Palei, R.C. Cavalli, F.M. Araujo, E.S. Ramos, G. Duarte, et al. (2008) eNOS haplotypes associated with gestational hypertension or preeclampsia. Pharmacogenomics 9(10), 1467-1473.
161. D. Colomba, G. Duro, S. Corrao, C. Argano, T. Di Chiara, D. Nuzzo, et al. (2008) Endothelial nitric oxide synthase gene polymorphisms and cardiovascular damage in hypertensive subjects: an Italian case-control study. Immun Ageing 5 4.
162. G. Dell'Omo, G. Penno, L. Pucci, C. Fotino, D. Lucchesi, S. Del Prato, et al. (2007) Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men. J Hypertens 25(7), 1389-1395.
163. O.J. Kim, U.K. Kim, S.H. Oh, Y.W. Cho, K.I. Oh, D. Oh, et al. (2010) Association of endothelial nitric oxide synthase polymorphisms and haplotypes with ischemic stroke in Korean individuals with or without diabetes mellitus. Mol Med Report 3(3), 509-513.
164. K.G. Santos, D. Crispim, L.H. Canani, P.T. Ferrugem, J.L. Gross and I. Roisenberg (2011) Association of eNOS gene polymorphisms with renal disease in caucasians with type 2 diabetes. Diabetes Res Clin Pract 91(3), 353-362.
165. T.S. Ahluwalia, M. Ahuja, T.S. Rai, H.S. Kohli, K. Sud, A. Bhansali, et al. (2008) Endothelial nitric oxide synthase gene haplotypes and diabetic nephropathy among Asian Indians. Mol Cell Biochem 314(1–2), 9-17.
166. V.C. Sandrim, R.W. de Syllos, H.R. Lisboa, G.S. Tres and J.E. Tanus-Santos (2007) Influence of eNOS haplotypes on the plasma nitric oxide products concentrations in hypertensive and type 2 diabetes mellitus patients. Nitric Oxide 16(3), 348-355.
167. K. Rittig, K. Holder, J. Stock, O. Tschritter, A. Peter, N. Stefan, et al. (2008) Endothelial NO-synthase intron 4 polymorphism is associated with disturbed in vivo nitric oxide production in individuals prone to type 2 diabetes. Horm Metab Res 40(1), 13-17.
168. S. Nagassaki, J.T. Sertorio, I.F. Metzger, A.F. Bem, J.B. Rocha and J.E. Tanus-Santos (2006) eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic Biol Med 41(7), 1044-1049.
169. D.C. Souza-Costa, V.C. Sandrim, L.F. Lopes, R.F. Gerlach, E.M. Rego and J.E. Tanus-Santos (2007) Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 193(2), 438-444.
170. C.H. Sponton, T.M. Rezende, P.A. Mallagrino, C.F. Franco-Penteado, M.A. Bezerra and A. Zanesco (2010) Women with TT genotype for eNOS gene are more responsive in lowering blood pressure in response to exercise. Eur J Cardiovasc Prev Rehabil 17(6), 676-681.
171. V.C. Sandrim, A.C. Palei, M.R. Luizon, T.C. Izidoro-Toledo, R.C. Cavalli and J.E. Tanus-Santos (2010) eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J 10(1), 40-45.
172. S. Alfadhli, B. AlTamimy, K. AlSaeid and M. Haider (2011) Endothelial nitric oxide synthase gene haplotype association with systemic lupus erythematosus. Lupus 20(7), 700-708.
173. F.Y. Tang, X.W. Xie, G.H. Ling and F.Y. Liu (2010) Endothelial nitric oxide synthase and nicotinamide adenosine dinucleotide phosphate oxidase p22phox gene (C242T) polymorphisms and systemic lupus erythematosus in a Chinese population. Lupus 19(2), 192-196.
174. K. Yanamandra, D. Napper, A. Pramanik, J.A. Bocchini Jr and R. Dhanireddy (2010) Endothelial nitric oxide synthase genotypes in the etiology of retinopathy of prematurity in premature infants. Ophthalmic Genet 31(4), 173-177.
175. J.L. Wang, H.G. Wang, H.Q. Gao, G.X. Zhai, P. Chang and Y.G. Chen (2010) Endothelial nitric oxide synthase polymorphisms and erectile dysfunction: a meta-analysis. J Sex Med 7(12), 3889-3898.
176. B. Erol, G. Bozdogan, B. Akduman, A. Dursun, S. Bozdogan, K. Onem, et al. (2009) eNOS gene intron 4 VNTR and exon 7-G894T polymorphisms in Turkish men with erectile dysfunction: a case control study. J Sex Med 6(5), 1423-1429.
177. N. Kuptsova, J. Chang-Claude, S. Kropp, I. Helmbold, P. Schmezer, D. von Fournier, et al. (2008) Genetic predictors of long-term toxicities after radiation therapy for breast cancer. Int J Cancer 122(6), 1333-1339.
178. J. Lu, Q. Wei, M.L. Bondy, T.K. Yu, D. Li, A. Brewster, et al. (2006) Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 107(9), 2245-2253.
179. J.C. Rodriguez-Perez, A. Macias-Reyes, A. Jimenez-Sosa, O. Companioni, F.J. Rodriguez-Esparragon, M.A. Cobo, et al. (2009) A synergistic association of ACE I/D and eNOS G894T gene variants with the progression of immunoglobulin a nephropathy—a pilot study. Am J Nephrol 30(3), 303-309.
180. B. Spoto, F.A. Benedetto, A. Testa, G. Tripepi, F. Mallamaci, R. Maas, et al. (2007) An additive effect of endothelial nitric oxide synthase gene polymorphisms contributes to the severity of atherosclerosis in patients on dialysis. Am J Hypertens 20(7), 758-763.
181. T. Kobayashi, F. Ushikubi and S. Narumiya (2000) Amino acid residues conferring ligand binding properties of prostaglandin I and prostaglandin D receptors. Identification by site-directed mutagenesis. J Biol Chem 275(32), 24294-24303.
182. S. Moncada, R. Gryglewski, S. Bunting and J.R. Vane (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263(5579), 663-665.
183. R.J. Gryglewski, S. Bunting, S. Moncada, R.J. Flower and J.R. Vane (1976) Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 12(5), 685-713.
184. M.J. Cho and M.A. Allen (1978) Chemical stability of prostacyclin (PGI2) in aqueous solutions. Prostaglandins 15(6), 943-954.
185. G.J. Dusting, S. Moncada and J.R. Vane (1978) Recirculation of prostacyclin (PGI2) in the dog. Br J Pharmacol 64(2), 315-320.
186. A.L. Tsai, M.J. Hsu, W. Patsch and K.K. Wu (1991) Regulation of PGI2 activity by serum proteins: serum albumin but not high density lipoprotein is the PGI2 binding and stabilizing protein in human blood. Biochim Biophys Acta 1115(2), 131-140.
187. L. Parente and M. Perretti (2003) Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 65(2), 153-159.
188. L.J. Marnett, S.W. Rowlinson, D.C. Goodwin, A.S. Kalgutkar and C.A. Lanzo (1999) Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem 274(33), 22903-22906.
189. W.L. Smith, D.L. DeWitt and R.M. Garavito (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69 145-182.
190. S. Narumiya, Y. Sugimoto and F. Ushikubi (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev 79(4), 1193-1226.
191. B.B. Weksler, A.J. Marcus and E.A. Jaffe (1977) Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci USA 74(9), 3922-3926.
192. C. Ingerman-Wojenski, M.J. Silver, J.B. Smith and E. Macarak (1981) Bovine endothelial cells in culture produce thromboxane as well as prostacyclin. J Clin Invest 67(5), 1292-1296.
193. S. Moncada (1982) Biological importance of prostacyclin. Br J Pharmacol 76(1), 3-31. Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980
194. S. Bunting, S. Moncada and J.R. Vane (1983) The prostacyclin–thromboxane A2 balance: pathophysiological and therapeutic implications. Br Med Bull 39(3), 271-276.
195. W.L. Smith, D.L. DeWitt and M.L. Allen (1983) Bimodal distribution of the prostaglandin I2 synthase antigen in smooth muscle cells. J Biol Chem 258(9), 5922-5926.
196. J.A. Oates, G.A. FitzGerald, R.A. Branch, E.K. Jackson, H.R. Knapp and L.J. Roberts II (1988) Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med 319(11), 689-698.
197. Y. Lin, K.K. Wu and K.H. Ruan (1998) Characterization of the secondary structure and membrane interaction of the putative membrane anchor domains of prostaglandin I2 synthase and cytochrome P450 2C1. Arch Biochem Biophys 352(1), 78-84.
198. K.H. Ruan, S.P. So, W. Zheng, J. Wu, D. Li and J. Kung (2002) Solution structure and topology of the N-terminal membrane anchor domain of a microsomal cytochrome P450: prostaglandin I2 synthase. Biochem J 368(Pt. 3), 721-728.
199. M.L. Massimino, C. Griffoni, E. Spisni, M. Toni and V. Tomasi (2002) Involvement of caveolae and caveolae-like domains in signalling, cell survival and angiogenesis. Cell Signal 14(2), 93-98.
200. W.L. Smith (1986) Prostaglandin biosynthesis and its compartmentation in vascular smooth muscle and endothelial cells. Annu Rev Physiol 48 251-262.
201. H. Deng, A. Huang, S.P. So, Y.Z. Lin and K.H. Ruan (2002) Substrate access channel topology in membrane-bound prostacyclin synthase. Biochem J 362(Pt. 3), 545-551.
202. K.H. Ruan, H. Deng, J. Wu and S.P. So (2005) The N-terminal membrane anchor domain of the membrane-bound prostacyclin synthase involved in the substrate presentation of the coupling reaction with cyclooxygenase. Arch Biochem Biophys 435(2), 372-381.
203. E. Spisni, C. Griffoni, S. Santi, M. Riccio, R. Marulli, G. Bartolini, et al. (2001) Colocalization prostacyclin (PGI2) synthase–caveolin-1 in endothelial cells and new roles for PGI2 in angiogenesis. Exp Cell Res 266(1), 31-43.
204. M.L. Wade, N.F. Voelkel and F.A. Fitzpatrick (1995) “Suicide” inactivation of prostaglandin I2 synthase: Characterization of mechanism-based inactivation with isolated enzyme and endothelial cells. Arch Biochem Biophys 321(2), 453-458.
205. M. Zou, C. Martin and V. Ullrich (1997) Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol Chem 378(7), 707-713.
206. P. Schmidt, N. Youhnovski, A. Daiber, A. Balan, M. Arsic, M. Bachschmid, et al. (2003) Specific nitration at tyrosine 430 revealed by high resolution mass spectrometry as basis for redox regulation of bovine prostacyclin synthase. J Biol Chem 278(15), 12813-12819.
207. A.K. Dutta-Roy and A.K. Sinha (1987) Purification and properties of prostaglandin E1/prostacyclin receptor of human blood platelets. J Biol Chem 262(26), 12685-12691.
208. A.L. Tsai, M.J. Hsu, H. Vijjeswarapu and K.K. Wu (1989) Solubilization of prostacyclin membrane receptors from human platelets. J Biol Chem 264(1), 61-67.
209. R.L. Jones, Y. Qian, H.N. Wong, H. Chan and A.P. Yim (1997) Prostanoid action on the human pulmonary vascular system. Clin Exp Pharmacol Physiol 24(12), 969-972.
210. O. Nakagawa, I. Tanaka, T. Usui, M. Harada, Y. Sasaki, H. Itoh, et al. (1994) Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 90(4), 1643-1647.
211. E.M. Smyth and G.A. FitzGerald (2002) Human prostacyclin receptor. Vitam Horm 65 149-165.
212. Y. Ogawa, I. Tanaka, M. Inoue, Y. Yoshitake, N. Isse, O. Nakagawa, et al. (1995) Structural organization and chromosomal assignment of the human prostacyclin receptor gene. Genomics 27(1), 142-148.
213. P.J. Leigh, W.A. Cramp and J. MacDermot (1984) Identification of the prostacyclin receptor by radiation inactivation. J Biol Chem 259(20), 12431-12436.
214. T. Kobayashi, M. Kiriyama, T. Hirata, M. Hirata, F. Ushikubi and S. Narumiya (1997) Identification of domains conferring ligand binding specificity to the prostanoid receptor. Studies on chimeric prostacyclin/prostaglandin D receptors. J Biol Chem 272(24), 15154-15160.
215. R.A. Armstrong (1996) Platelet prostanoid receptors. Pharmacol Ther 72(3), 171-191.
216. Y. Boie, T.H. Rushmore, A. Darmon-Goodwin, R. Grygorczyk, D.M. Slipetz, K.M. Metters, et al. (1994) Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem 269(16), 12173-12178.
217. C.Y. Xiao, A. Hara, K. Yuhki, T. Fujino, H. Ma, Y. Okada, et al. (2001) Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 104(18), 2210-2215.
218. H. Wise, Y.H. Wong and R.L. Jones (2002) Prostanoid signal integration and cross talk. Neurosignals 11(1), 20-28.
219. Z. Zhang, S.C. Austin and E.M. Smyth (2001) Glycosylation of the human prostacyclin receptor: role in ligand binding and signal transduction. Mol Pharmacol 60(3), 480-487.
220. J.S. Hayes, O.A. Lawler, M.T. Walsh and B.T. Kinsella (1999) The prostacyclin receptor is isoprenylated. Isoprenylation is required for efficient receptor-effector coupling. J Biol Chem 274(34), 23707-23718.
221. S.M. Miggin, O.A. Lawler and B.T. Kinsella (2002) Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. Eur J Biochem 269(6), 1714-1725.
222. S. Giovanazzi, M.R. Accomazzo, O. Letari, D. Oliva and S. Nicosia (1997) Internalization and down-regulation of the prostacyclin receptor in human platelets. Biochem J 325(Pt. 1), 71-77.
223. E.M. Smyth, W.H. Li and G.A. FitzGerald (1998) Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase C. J Biol Chem 273(36), 23258-23266.
224. S.M. Miggin, O.A. Lawler and B.T. Kinsella (2003) Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem 278(9), 6947-6958.
225. P.A. Modesti, R. Abbate, D. Prisco and G.F. Gensini (1990) Human prostacyclin platelet receptors and platelet lipid composition. J Lipid Mediat 2(6), 309-315.
226. Y. Sasaki, T. Takahashi, I. Tanaka, K. Nakamura, Y. Okuno, O. Nakagawa, et al. (1997) Expression of prostacyclin receptor in human megakaryocytes. Blood 90(3), 1039-1046.
227. J. Svensson, M. Hamberg and B. Samuelsson (1976) On the formation and effects of thromboxane A2 in human platelets. Acta Physiol Scand 98(3), 285-294.
228. S. Moncada and J.R. Vane (1978) Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30(3), 293-331.
229. S. Moncada and J.R. Vane (1980) Prostacyclin in the cardiovascular system. Adv Prostaglandin Thromboxane Res 6 43-60.
230. P. Needleman, J. Turk, B.A. Jakschik, A.R. Morrison and J.B. Lefkowith (1986) Arachidonic acid metabolism. Annu Rev Biochem 55 69-102.
231. J.S. Pober and R.S. Cotran (1990) Cytokines and endothelial cell biology. Physiol Rev 70(2), 427-451.
232. J.M. Manganello, Y. Djellas, C. Borg, K. Antonakis and G.C. Le Breton (1999) Cyclic AMP-dependent phosphorylation of thromboxane A(2) receptor-associated Galpha(13). J Biol Chem 274(39), 28003-28010.
233. J. Panes, M. Perry and D.N. Granger (1999) Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol 126(3), 537-550.
234. R.R. Gorman, S. Bunting and O.V. Miller (1977) Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13(3), 377-388.
235. J.E. Tateson, S. Moncada and J.R. Vane (1977) Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 13(3), 389-397.
236. H. Wise and R.L. Jones (2000) Prostacyclin and its receptors New York: Kluwer Academic/Plenum Publishers
237. A.L. Gonzalez-Utor, I. Sanchez-Aguayo and J. Hidalgo (1992) Cytochemical localization of K(+)-dependent p-nitrophenyl phosphatase and adenylate cyclase by using one-step method in human washed platelets. Histochemistry 97(6), 503-507.
238. W. Seiss (1989) Molecular mechanisms of platelet activation. Physiol Rev 69 58-178.
239. J.E. Fox, A.K. Say and R.J. Haslam (1979) Subcellular distribution of the different platelet proteins phosphorylated on exposure of intact platelets to ionophore A23187 or to prostaglandin E1. Possible role of a membrane phosphopolypeptide in the regulation of calcium-ion transport. Biochem J 184(3), 651-661.
240. R. Kaser-Glanzmann, E. Gerber and E.F. Luscher (1979) Regulation of the intracellular calcium level in human blood platelets: cyclic adenosine 3',5'-monophosphate dependent phosphorylation of a 22,000 dalton component in isolated Ca2+-accumulating vesicles. Biochim Biophys Acta 558(3), 344-347.
241. D.R. Hathaway, C.R. Eaton and R.S. Adelstein (1981) Regulation of human platelet myosin light chain kinase by the catalytic subunit of cyclic AMP-dependent protein kinase. Nature 291(5812), 252-256.
242. L. Cavallini, M. Coassin, A. Borean and A. Alexandre (1996) Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation. J Biol Chem 271(10), 5545-5551.
243. A. Aszodi, A. Pfeifer, M. Ahmad, M. Glauner, X.H. Zhou, L. Ny, et al. (1999) The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. Embo J 18(1), 37-48.
244. W. Siess and E.G. Lapetina (1989) Prostacyclin inhibits platelet aggregation induced by phorbol ester or Ca2+ ionophore at steps distal to activation of protein kinase C and Ca2+-dependent protein kinases. Biochem J 258(1), 57-65.
245. M.A. Conti and R.S. Adelstein (1981) The relationship between calmodulin binding and phosphorylation of smooth muscle myosin kinase by the catalytic subunit of 3':5' cAMP-dependent protein kinase. J Biol Chem 256(7), 3178-3181.
246. J.E. Fox and D.R. Phillips (1982) Role of phosphorylation in mediating the association of myosin with the cytoskeletal structures of human platelets. J Biol Chem 257(8), 4120-4126.
247. S.C. Body (1996) Platelet activation and interactions with the microvasculature. J Cardiovasc Pharmacol 27(Suppl. 1), S13-S25.
248. S. Narumiya and G.A. FitzGerald (2001) Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 108(1), 25-30.
249. E.M. Smyth, S.C. Austin, M.P. Reilly and G.A. FitzGerald (2000) Internalization and sequestration of the human prostacyclin receptor. J Biol Chem 275(41), 32037-32045.
250. B. Ashby (1992) Comparison of Iloprost, cicaprost and prostacyclin effects on cyclic AMP metabolism in intact platelets. Prostaglandins 43(3), 255-261.
251. H. Darius, K. Veit, C. Binz, A. Fisch and J. Meyer (1995) Diminished inhibition of adhesion molecule expression in prostacyclin receptor desensitized human platelets. Agents Actions Suppl 45 77-83.
252. K. Jaschonek, K.R. Karsch, H. Weisenberger, S. Tidow, C. Faul and W. Renn (1986) Platelet prostacyclin binding in coronary artery disease. J Am Coll Cardiol 8(2), 259-266.
253. W. Klockenbusch, T. Hohlfeld, M. Wilhelm, T. Somville and K. Schror (1996) Platelet PGI2 receptor affinity is reduced in pre-eclampsia. Br J Clin Pharmacol 41(6), 616-618.
254. P.A. Modesti, A. Fortini, L. Poggesi, M. Boddi, R. Abbate and G.F. Gensini (1987) Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man. Thromb Res 48(6), 663-669.
255. U. Alt, P.J. Leigh, A.J. Wilkins, P.K. Morris and J. MacDermot (1986) Desensitization of iloprost responsiveness in human platelets follows prolonged exposure to iloprost in vitro. Br J Clin Pharmacol 22(1), 118-119.
256. H. Darius, C. Binz, K. Veit, A. Fisch and J. Meyer (1995) Platelet receptor desensitization induced by elevated prostacyclin levels causes platelet–endothelial cell adhesion. J Am Coll Cardiol 26(3), 800-806.
257. A. Krane, J. MacDermot and M. Keen (1994) Desensitization of adenylate cyclase responses following exposure to IP prostanoid receptor agonists. Homologous and heterologous desensitization exhibit the same time course. Biochem Pharmacol 47(6), 953-959.
258. H. Sinzinger, K. Silberbauer, A.K. Horsch and A. Gall (1981) Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease—a rebound phenomenon? Prostaglandins 21(1), 49-51.
259. J. MacDermot (1986) Desensitization of prostacyclin responsiveness in platelets. Apparent differences in the mechanism in vitro or in vivo. Biochem Pharmacol 35(16), 2645-2649.
260. A. Fisch, K. Tobusch, K. Veit, J. Meyer and H. Darius (1997) Prostacyclin receptor desensitization is a reversible phenomenon in human platelets. Circulation 96(3), 756-760.
261. B. Ashby (1994) Interactions among prostaglandin receptors. Receptor 4(1), 31-42.
262. S.J. Wilson, A.M. Roche, E. Kostetskaia and E.M. Smyth (2004) Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. J Biol Chem 279(51), 53036-53047.
263. S. Ortiz-Vega and B. Ashby (1997) Human prostacyclin receptor: cloning and co-expression with EP3 prostaglandin receptor. Adv Exp Med Biol 433 235-238.
264. B.Z. Paul, B. Ashby and S.B. Sheth (1998) Distribution of prostaglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells. Br J Haematol 102(5), 1204-1211.
265. S. Moncada and J.R. Vane (1979) Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 300(20), 1142-1147.
266. K.A. Jorgensen (1982) Studies on the biological balance between thromboxanes and prostacyclins in relation to the platelet-vessel wall interaction. Dan Med Bull 29(4), 169-197.
267. A.J. Marcus, M.J. Broekman and D.J. Pinsky (2002) COX inhibitors and thromboregulation. N Engl J Med 347(13), 1025-1026.
268. R. Coleman, I. Kennedy, P. Humphrey, et al. (1990) Prostanoids and their receptors. J. Emmett (Eds) Comprehensive medicinal chemistry: membranes and receptors Oxford: Pergamon Press 643-714.
269. W.L. Smith, D.L. DeWitt, T. Shimokawa, S.A. Kraemer and E.A. Meade (1990) Molecular basis for the inhibition of prostanoid biosynthesis by nonsteroidal anti-inflammatory agents. Stroke 21(12 Suppl.), IV24-IV28.
270. W.L. Smith (1992) Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263(2, Pt. 2), F181-F191.
271. M. Minkes, N. Stanford, M.M. Chi, G.J. Roth, A. Raz, P. Needleman, et al. (1977) Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions. J Clin Invest 59(3), 449-454.
272. C. Malmsten, E. Granstrom and B. Samuelsson (1976) Cyclic AMP inhibits synthesis of prostaglandin endoperoxide (PGG2) in human platelets. Biochem Biophys Res Commun 68(2), 569-576.
273. J.M. Gerrard, J.D. Peller, T.P. Krick and J.G. White (1977) Cyclic AMP and platelet prostaglandin synthesis. Prostaglandins 14(1), 39-50.
274. P. Nony, P. Ffrench, P. Girard, S. Delair, S. Azoulay, J.P. Girre, et al. (1996) Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects. Can J Physiol Pharmacol 74(8), 887-893.
275. A.J. Marcus, B.B. Weksler, E.A. Jaffe and M.J. Broekman (1980) Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 66(5), 979-986.
276. G.E. Caughey, L.G. Cleland, J.R. Gamble and M.J. James (2001) Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets. Role of thromboxane A2. J Biol Chem 276(41), 37839-37845.
277. M.W. Radomski, R.M. Palmer and S. Moncada (1987) The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 92(3), 639-646.
278. P.S. Lidbury, E. Antunes, G. de Nucci and J.R. Vane (1989) Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation. Br J Pharmacol 98(4), 1275-1280.
279. M.W. Radomski, M.J. Palmer and S. Moncada (1987) The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 148 1482-1489.
280. L. Panicot-Dubois, G.M. Thomas, B.C. Furie, B. Furie, D. Lombardo and C. Dubois (2007) Bile salt-dependent lipase interacts with platelet CXCR4 and modulates thrombus formation in mice and humans. J Clin Invest 117(12), 3708-3719.
281. J.R. Vane and R.M. Botting (1995) Pharmacodynamic profile of prostacyclin. Am J Cardiol 75(3), 3A-10A.
282. G.A. FitzGerald, B. Smith, A.K. Pedersen and A.R. Brash (1984) Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 310(17), 1065-1068.
283. C. Yokoyama, T. Yabuki, M. Shimonishi, M. Wada, T. Hatae, S. Ohkawara, et al. (2002) Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 106(18), 2397-2403.
284. R.H. Bourgain (1978) Inhibition of PGI2 (prostacyclin) synthesis in the arterial wall enhances the formation of white platelet thrombi in vivo. Haemostasis 7(4), 252-255.
285. L.C. Pettigrew and K.K. Wu (1986) Platelet function and antiaggregant therapy in ischemic stroke. Semin Neurol 6(3), 293-298.
286. J. Vane (1985) Prostacyclin in the cardiovascular system in health and disease. K. Schror (Eds) Prostaglandins and other eicosanoids in the cardiovascular system Basel: Karger 7-28.
287. R.W. Stein, A.C. Papp, W.J. Weiner and K.K. Wu (1985) Reduction of serum prostacyclin stability in ischemic stroke. Stroke 16(1), 16-18.
288. S. Akopov, V. Darbinian, G. Grigorian, A. Kosyan and E. Gabrielian (1993) Elevated velocity of prostacyclin degradation in blood as a possible risk factor in patients with cerebrovascular disorders. Eur Neurol 33(3), 252-255.
289. Y. Numaguchi, K. Naruse, M. Harada, H. Osanai, S. Mokuno, K. Murase, et al. (1999) Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol 19(3), 727-733.
290. M. Harada, Y. Toki, Y. Numaguchi, H. Osanai, T. Ito, K. Okumura, et al. (1999) Prostacyclin synthase gene transfer inhibits neointimal formation in rat balloon-injured arteries without bleeding complications. Cardiovasc Res 43(2), 481-491.
291. Y. Uchiyama-Tsuyuki, K. Kawashima, H. Araki and S. Otomo (1995) Prostacyclin analogue TTC-909 reduces memory impairment in rats with cerebral embolism. Pharmacol Biochem Behav 52(3), 555-559.
292. C.T. Stier Jr, P.N. Chander, A. Belmonte, R.S. Inamdar and M. Mistry (1997) Beneficial action of beraprost sodium, a prostacyclin analog, in stroke-prone rats. J Cardiovasc Pharmacol 30(3), 285-293.
293. J. Huczynski, E. Kostka-Trabka, W. Sotowska, K. Bieron, L. Grodzinska, A. Dembinska-Kiec, et al. (1985) Double-blind controlled trial of the therapeutic effects of prostacyclin in patients with completed ischaemic stroke. Stroke 16(5), 810-814.
294. J.F. Martin, N. Hamdy, J. Nicholl, N. Lewtas, U. Bergvall, P. Owen, et al. (1985) Prostacyclin in cerebral infarction. N Engl J Med 312(25), 1642.
295. C.Y. Hsu, R.E. Faught Jr, A.J. Furlan, B.M. Coull, D.C. Huang, E.L. Hogan, et al. (1987) Intravenous prostacyclin in acute nonhemorrhagic stroke: a placebo-controlled double-blind trial. Stroke 18(2), 352-358.
296. L.J. Rubin (1995) Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol 75(3), 51A-54A.
297. D.J. Fitzgerald, S.S. Entman, K. Mulloy and G.A. FitzGerald (1987) Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. Circulation 75(5), 956-963.
298. T. Murata, F. Ushikubi, T. Matsuoka, M. Hirata, A. Yamasaki, Y. Sugimoto, et al. (1997) Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388(6643), 678-682.
299. A. Ueno, H. Naraba, Y. Ikeda, F. Ushikubi, T. Murata, S. Narumiya, et al. (2000) Intrinsic prostacyclin contributes to exudation induced by bradykinin or carrageenin: a study on the paw edema induced in IP-receptor-deficient mice. Life Sci 66(12), PL155-PL160.
300. Y. Cheng, S.C. Austin, B. Rocca, B.H. Koller, T.M. Coffman, T. Grosser, et al. (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296(5567), 539-541.
301. J. Yang, J. Wu, H. Jiang, R. Mortensen, S. Austin, D.R. Manning, et al. (2002) Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem 277(48), 46035-46042.
302. K.M. Egan, J.A. Lawson, S. Fries, B. Koller, D.J. Rader, E.M. Smyth, et al. (2004) COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306(5703), 1954-1957.
303. P.W. Majerus (1983) Arachidonate metabolism in vascular disorders. J Clin Invest 72(5), 1521-1525.
304. E.A. de Deckere, D.H. Nugteren and F. Ten Hoor (1977) Prostacyclin is the major prostaglandin released from the isolated perfused rabbit and rat heart. Nature 268(5616), 160-163.
305. S.J. Coker, J.R. Parratt, I.M. Ledingham and I.J. Zeitlin (1981) Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 291(5813), 323-324.
306. G. Johnson III, L.E. Furlan, N. Aoki and A.M. Lefer (1990) Endothelium and myocardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats. Circ Res 66(5), 1362-1370.
307. P.J. Simpson, J. Mickelson, J.C. Fantone, K.P. Gallagher and B.R. Lucchesi (1987) Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart. Circ Res 60(5), 666-673.
308. P.J. Simpson, S.E. Mitsos, A. Ventura, K.P. Gallagher, J.C. Fantone, G.D. Abrams, et al. (1987) Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. Am Heart J 113(1), 129-137.
309. T. Aherne, D.C. Price, E.S. Yee, W.R. Hsieh and P.A. Ebert (1986) Prevention of ischemia-induced myocardial platelet deposition by exogenous prostacyclin. J Thorac Cardiovasc Surg 92(1), 99-104.
310. N.N. Kahn, W.A. Bauman and A.K. Sinha (1996) Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury. Proc Natl Acad Sci USA 93(1), 245-249.
311. G.G. Neri Serneri, P.A. Modesti, A. Fortini, R. Abbate, A. Lombardi and G.F. Gensini (1984) Reduction in prostacyclin platelet receptors in active spontaneous angina. Lancet 2(8407), 838-841.
312. D.J. Betteridge, K.E. El Tahir, J.P. Reckless and K.I. Williams (1982) Platelets from diabetic subjects show diminished sensitivity to prostacyclin. Eur J Clin Invest 12(5), 395-398.
313. K. Jaschonek, H. Weisenberger, K.R. Karsch, W. Renn, W. Daiss, D. Schenzle, et al. (1984) Impaired platelet prostacyclin binding in acute myocardial infarction. Lancet 2(8415), 1341-1342.
314. K. Jaschonek and C.P. Muller (1988) Platelet and vessel associated prostacyclin and thromboxane A2/prostaglandin endoperoxide receptors. Eur J Clin Invest 18(1), 1-8.
315. C. Sturzebecher Sr, M. Haberey, B. Muller, E. Schillinger, G. Schroder, W. Skuballa, et al. (1985) Pharmacological profile of ZK 96480, a new chemically and metabolically stable prostacyclin analogue with oral availability and high PGI2 intrinsic activity. K. Schror (Eds) Prostaglandins and other eicosanoids in the cardiovascular system Basel: Karger 485-491.
316. K. Schror, H. Darius, R. Matzky and R. Ohlendorf (1981) The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374)—equipotent to PGI2 in vitro. Naunyn Schmiedebergs Arch Pharmacol 316(3), 252-255.
317. B.J. Whittle, S. Moncada, F. Whiting and J.R. Vane (1980) Carbacyclin—a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins 19(4), 605-627.
318. B.J. Whittle and S. Moncada (1985) Platelet actions of stable carbocyclic analogues of prostacyclin. Circulation 72(6), 1219-1225.
319. R.C. Nickolson, M.H. Town and H. Vorbruggen (1985) Prostacyclin-analogs. Med Res Rev 5(1), 1-53.
320. D.B. Badesch, V.V. McLaughlin, M. Delcroix, C.D. Vizza, H. Olschewski, O. Sitbon, et al. (2004) Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 43(12, Suppl. S), 56S-61S.
321. A.J. Kooter, R.G. Ijzerman, O. Kamp, A.B. Boonstra and Y.M. Smulders (2010) No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial. BMC Pulm Med 10 18.
322. T. Wienecke, J. Olesen, P.S. Oturai and M. Ashina (2008) Prostacyclin (epoprostenol) induces headache in healthy subjects. Pain 139(1), 106-116.
323. T. Wienecke, J. Olesen and M. Ashina (2010) Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs. Cephalalgia 30(2), 179-190.
324. D.B. Badesch, M.D. McGoon, R.J. Barst, V.F. Tapson, L.J. Rubin, F.M. Wigley, et al. (2009) Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol 36(10), 2244-2249.
325. S. Akagi, K. Nakamura, K. Miyaji, A. Ogawa, K.F. Kusano, H. Ito, et al. (2010) Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Circ J 74(10), 2200-2205.
326. T.A. Khan, G. Schnickel, D. Ross, S. Bastani, H. Laks, F. Esmailian, et al. (2009) A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. J Thorac Cardiovasc Surg 138(6), 1417-1424.
327. T. Nakayama, Y. Masubuchi, K. Kawauchi, R. Masaki, T. Hironaga, H. Ishima, et al. (2007) Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction. Prostaglandins Leukot Essent Fatty Acids 76(6), 309-314.
328. T. Kunieda, N. Nakanishi, H. Matsubara, T. Ohe, Y. Okano, H. Kondo, et al. (2009) Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension. Int Heart J 50(4), 513-529.
329. K. Theodoraki, D. Tsiapras, L. Tsourelis, D. Zarkalis, P. Sfirakis, E. Kapetanakis, et al. (2006) Inhaled iloprost in eight heart transplant recipients presenting with post-bypass acute right ventricular dysfunction. Acta Anaesthesiol Scand 50(10), 1213-1217.
330. V.V. McLaughlin, R.J. Oudiz, A. Frost, V.F. Tapson, S. Murali, R.N. Channick, et al. (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174(11), 1257-1263.
331. R.P. Baughman, M.A. Judson, E.E. Lower, K. Highland, S. Kwon, N. Craft, et al. (2009) Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 26(2), 110-120.
332. O. Sitbon, A. Manes, X. Jais, M. Pallazini, M. Humbert, L. Presotto, et al. (2007) Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol 49(1), 1-5.
333. M. Rubenfire, V.V. McLaughlin, R.P. Allen, G. Elliott, M.H. Park, M. Wade, et al. (2007) Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest 132(3), 757-763.
334. R. Voswinckel, B. Enke, F. Reichenberger, M. Kohstall, A. Kreckel, S. Krick, et al. (2006) Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 48(8), 1672-1681.
335. R.N. Channick, H. Olschewski, W. Seeger, T. Staub, R. Voswinckel and L.J. Rubin (2006) Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 48(7), 1433-1437.
336. N. Skoro-Sajer, D. Bonderman, F. Wiesbauer, E. Harja, J. Jakowitsch, W. Klepetko, et al. (2007) Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 5(3), 483-489.
337. V.V. McLaughlin, R.L. Benza, L.J. Rubin, R.N. Channick, R. Voswinckel, V.F. Tapson, et al. (2010) Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 55(18), 1915-1922.
338. J. Hiremath, S. Thanikachalam, K. Parikh, S. Shanmugasundaram, S. Bangera, L. Shapiro, et al. (2010) Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant 29(2), 137-149.
339. A. Balbir-Gurman, Y. Braun-Moscovici, V. Livshitz, D. Schapira, D. Markovits, A. Rozin, et al. (2007) Antioxidant status after iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis. Clin Rheumatol 26(9), 1517-1521.
340. A. Volpe, D. Biasi, P. Caramaschi, L.M. Bambara, A. Carletto, M. Degan, et al. (2008) Iloprost infusion does not reduce oxidative stress in systemic sclerosis. Rheumatol Int 28(4), 335-337.
341. P. Caramaschi, A. Volpe, I. Tinazzi, L.M. Bambara, A. Carletto and D. Biasi (2006) Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results. Rheumatol Int 27(2), 203-205.
342. G. Lessiani, N. Vazzana, C. Cuccurullo, D. Di Michele, G. Laurora, G. Sgro, et al. (2011) Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. Thromb Haemost 105(2), 321-328.
343. M.A. Creager, R.L. Pande and W.R. Hiatt (2008) A. randomized trial of iloprost in patients with intermittent claudication. Vasc Med 13(1), 5-13.
344. H. Moriya, K. Ishioka, K. Honda, M. Oka, K. Maesato, R. Ikee, et al. (2010) Beraprost sodium, an orally active prostaglandin I(2) analog, improves renal anemia in hemodialysis patients with peripheral arterial disease. Ther Apher Dial 14(5), 472-476.
345. T. Matsumoto, K. Iwasa, R. Kyuragi, K. Honma, A. Guntani, T. Ohmine, et al. (2010) The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans. Int Angiol 29(2 Suppl.), 49-54.
346. A. Arcangeli, B. Rocca, G. Salvatori, M. Ciancia, R. De Cristofaro and M. Antonelli (2010) Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter. Thromb Res 126(1), 24-31.
347. L.P. Fabbri, M. Nucera, M. Al Malyan and C. Becchi (2010) Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiol Scand 54(1), 92-97.
348. K. Spargias, E. Adreanides, E. Demerouti, A. Gkouziouta, A. Manginas, G. Pavlides, et al. (2009) Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 120(18), 1793-1799.
349. K.M. Kim, H.W. Kim, J.H. Lee, J.W. Chang, J.S. Park and S.B. Kim (2009) Effects of beraprost sodium, an oral prostaglandin I2 analog, on hemostatic factors and inflammation in chronic peritoneal dialysis patients. Perit Dial Int 29(2), 178-181.
350. S. Moncada and J.L. Amezcua (1979) Prostacyclin, thromboxane A2 interactions in haemostasis and thrombosis. Haemostasis 8(3–5), 252-265.
351. J.R. Vane (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231(25), 232-235.
352. A. Lopez-Farre, C. Caramelo, A. Esteban, M.L. Alberola, I. Millas, M. Monton, et al. (1995) Effects of aspirin on platelet-neutrophil interactions. Role of nitric oxide and endothelin-1. Circulation 91(7), 2080-2088.
353. J.P. De La Cruz, E. Blanco and F. Sanchez de la Cuesta (2000) Effect of dipyridamole and aspirin on the platelet-neutrophil interaction via the nitric oxide pathway. Eur J Pharmacol 397(1), 35-41.
354. J.P. De La Cruz, M.M. Arrebola, A. Guerrero and F. Sanchez de la Cuesta (2002) Influence of nitric oxide on the in vivo antiaggregant effect of ticlopidine. Vascul Pharmacol 38(3), 183-186.
355. W.L. Smith, R.M. Garavito and D.L. DeWitt (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271(52), 33157-33160.
356. B.F. McAdam, F. Catella-Lawson, I.A. Mardini, S. Kapoor, J.A. Lawson and G.A. FitzGerald (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96(1), 272-277.
357. D. Pratico, C. Tillmann, Z.B. Zhang, H. Li and G.A. FitzGerald (2001) Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 98(6), 3358-3363.
358. T. Nakayama, M. Soma, Y. Takahashi, J. Uwabo, Y. Izumi and K. Kanmatsuse (1997) Novel polymorphic CA/TG repeat identified in the human prostacyclin synthase gene. Hum Hered 47(3), 176-177.
359. T. Nakayama, M. Soma, Y. Watanabe, B. Hasimu, K. Kanmatsuse, S. Kokubun, et al. (2003) Splicing mutation of the prostacyclin synthase gene in a family associated with hypertension. Adv Exp Med Biol 525 165-168.
360. T. Nakayama, M. Soma, Y. Watanabe, B. Hasimu, M. Sato, N. Aoi, et al. (2002) Splicing mutation of the prostacyclin synthase gene in a family associated with hypertension. Biochem Biophys Res Commun 297(5), 1135-1139.
361. T. Nakayama, M. Soma, A. Haketa, N. Aoi, K. Kosuge, M. Sato, et al. (2003) Haplotype analysis of the prostacyclin synthase gene and essential hypertension. Hypertens Res 26(7), 553-557.
362. S. Amano, K. Tatsumi, N. Tanabe, Y. Kasahara, K. Kurosu, Y. Takiguchi, et al. (2004) Polymorphism of the promoter region of prostacyclin synthase gene in chronic thromboembolic pulmonary hypertension. Respirology 9(2), 184-189.
363. N. Iwai, T. Katsuya, K. Ishikawa, T. Mannami, J. Ogata, J. Higaki, et al. (1999) Human prostacyclin synthase gene and hypertension: The Suita Study. Circulation 100(22), 2231-2236.
364. T. Nakayama, M. Soma and K. Kanmatsuse (1997) Organization of the human prostacyclin synthase gene and association analysis of a novel CA repeat in essential hypertension. Adv Exp Med Biol 433 127-130.
365. T. Nakayama, M. Soma, D. Rahmutula, Y. Izumi and K. Kanmatsuse (1997) Nonsense mutation of prostacyclin synthase gene in a family. Lancet 349(9069), 1887-1888.
366. T. Nakayama, M. Soma, D. Rahmutula, H. Tobe, M. Sato, J. Uwabo, et al. (2002) Association study between a novel single nucleotide polymorphism of the promoter region of the prostacyclin synthase gene and essential hypertension. Hypertens Res 25(1), 65-68.
367. T. Nakayama, M. Soma, D. Rehemudula, Y. Takahashi, H. Tobe, M. Satoh, et al. (2000) Association of 5' upstream promoter region of prostacyclin synthase gene variant with cerebral infarction. Am J Hypertens 13(12), 1263-1267.
368. T. Nakayama, M. Soma, S. Saito, J. Honye, J. Yajima, D. Rahmutula, et al. (2002) Association of a novel single nucleotide polymorphism of the prostacyclin synthase gene with myocardial infarction. Am Heart J 143(5), 797-801.
369. T. Nakayama, M. Soma, Y. Takahashi, D. Rehemudula, H. Tobe, M. Sato, et al. (2001) Polymorphism of the promoter region of prostacyclin synthase gene is not related to essential hypertension. Am J Hypertens 14(5 Pt 1), 409-411.
370. D. Chevalier, C. Cauffiez, C. Bernard, J.M. Lo-Guidice, D. Allorge, F. Fazio, et al. (2001) Characterization of new mutations in the coding sequence and 5'-untranslated region of the human prostacylcin synthase gene (CYP8A1). Hum Genet 108(2), 148-155.
371. D. Chevalier, D. Allorge, J.M. Lo-Guidice, C. Cauffiez, C. Lepetit, F. Migot-Nabias, et al. (2002) Sequence analysis, frequency and ethnic distribution of VNTR polymorphism in the 5'-untranslated region of the human prostacyclin synthase gene (CYP8A1). Prostaglandins Other Lipid Mediat 70(1–2), 31-37.
372. F.C. Luft (2000) Molecular genetics of human hypertension. Curr Opin Nephrol Hypertens 9(3), 259-266.
373. M. Barbalic, N.S. Narancic, T. Skaric-Juric, M.P. Salihovic, I.M. Klaric, L.B. Lauc, et al. (2009) A quantitative trait locus for SBP maps near KCNB1 and PTGIS in a population isolate. Am J Hypertens 22(6), 663-668.
374. X. Xie, Y.T. Ma, Z.Y. Fu, Y.N. Yang, X. Ma, B.D. Chen, et al. (2009) Association of polymorphisms of PTGS2 and CYP8A1 with myocardial infarction. Clin Chem Lab Med 47(3), 347-352.
375. R.N. Lemaitre, K. Rice, K. Marciante, J.C. Bis, T.S. Lumley, K.L. Wiggins, et al. (2009) Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis 204(2), e58-e63.
376. E.M. Poole, J. Bigler, J. Whitton, J.G. Sibert, J.D. Potter and C.M. Ulrich (2006) Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 15(3), 502-508.
377. R.S. Stearman, M.C. Grady, P. Nana-Sinkam, M. Varella-Garcia and M.W. Geraci (2007) Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines. Mol Cancer Res 5(3), 295-308.
378. K. Hashimoto, K. Ishibashi, T. Gebretsadik, T.V. Hartert, A. Yamamoto, T. Nakayama, et al. (2008) Functional polymorphism of the promoter region of the prostacyclin synthase gene and severity of RSV infection in hospitalized children. J Med Virol 80(11), 2015-2022.
379. J. Stitham, A. Stojanovic and J. Hwa (2002) Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism. J Biol Chem 277(18), 15439-15444.
380. B.M. Forman, J. Chen and R.M. Evans (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94(9), 4312-4317.
381. P. Patrignani, C. Di Febbo, S. Tacconelli, K. Douville, M.D. Guglielmi, R.J. Horvath, et al. (2008) Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. Pharmacogenet Genomics 18(7), 611-620.
382. J. Stitham, E. Arehart, L. Elderon, S.R. Gleim, K. Douville, Z. Kasza, et al. (2011) Comprehensive biochemical analysis of rare prostacyclin receptor variants: study of association of signaling with coronary artery obstruction. J Biol Chem 286(9), 7060-7069.
383. L. Plesner (1995) Ecto-ATPases: identities and functions. Int Rev Cytol 158 141-214.
384. H. Zimmermann (1999) Two novel families of ectonucleotidases: molecular structures, catalytic properties and a search for function. Trends Pharmacol Sci 20(6), 231-236.
385. T.F. Wang and G. Guidotti (1996) CD39 is an ecto-(Ca2+,Mg2+)-apyrase. J Biol Chem 271(17), 9898-9901.
386. E. Kaczmarek, K. Koziak, J. Sevigny, J.B. Siegel, J. Anrather, A.R. Beaudoin, et al. (1996) Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 271(51), 33116-33122.
387. A.J. Marcus, L.B. Safier, K.A. Hajjar, H.L. Ullman, N. Islam, M.J. Broekman, et al. (1991) Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells. J Clin Invest 88(5), 1690-1696.
388. H. Zimmermann (1992) 5'-Nucleotidase: molecular structure and functional aspects. Biochem J 285(Pt. 2), 345-365.
389. K.M. Dwyer, S.C. Robson, H.H. Nandurkar, D.J. Campbell, H. Gock, L.J. Murray-Segal, et al. (2004) Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 113(10), 1440-1446.
390. G.S. Kansas, G.S. Wood and TF. Tedder (1991) Expression, distribution, and biochemistry of human CD39. Role in activation-associated homotypic adhesion of lymphocytes. J Immunol 146(7), 2235-2244.
391. A.J. Marcus, M.J. Broekman, J.H. Drosopoulos, N. Islam, T.N. Alyonycheva, L.B. Safier, et al. (1997) The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 99(6), 1351-1360.
392. K.E. Dombrowski, J.M. Trevillyan, J.C. Cone, Y. Lu and C.A. Phillips (1993) Identification and partial characterization of an ectoATPase expressed by human natural killer cells. Biochemistry 32(26), 6515-6522.
393. C.R. Maliszewski, G.J. Delespesse, M.A. Schoenborn, R.J. Armitage, W.C. Fanslow, T. Nakajima, et al. (1994) The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization. J Immunol 153(8), 3574-3583.
394. K. Koziak, J. Sevigny, S.C. Robson, J.B. Siegel and E. Kaczmarek (1999) Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes. Thromb Haemost 82(5), 1538-1544.
395. J. Schulte am Esch II, J. Sevigny, E. Kaczmarek, J.B. Siegel, M. Imai, K. Koziak, et al. (1999) Structural elements and limited proteolysis of CD39 influence ATP diphosphohydrolase activity. Biochemistry 38(8), 2248-2258.
396. M. Handa and G. Guidotti (1996) Purification and cloning of a soluble ATP-diphosphohydrolase (apyrase) from potato tubers (Solanum tuberosum). Biochem Biophys Res Commun 218(3), 916-923.
397. A. Grinthal and G. Guidotti (2000) Substitution of His59 converts CD39 apyrase into an ADPase in a quaternary structure dependent manner. Biochemistry 39(1), 9-16.
398. J.H. Drosopoulos, M.J. Broekman, N. Islam, C.R. Maliszewski, R.B. Gayle III and A.J. Marcus (2000) Site-directed mutagenesis of human endothelial cell ecto-ADPase/soluble CD39: requirement of glutamate 174 and serine 218 for enzyme activity and inhibition of platelet recruitment. Biochemistry 39(23), 6936-6943.
399. E.G. Vasconcelos, P.S. Nascimento, M.N. Meirelles, S. Verjovski-Almeida and S.T. Ferreira (1993) Characterization and localization of an ATP-diphosphohydrolase on the external surface of the tegument of Schistosoma mansoni. Mol Biochem Parasitol 58(2), 205-214.
400. E.G. Vasconcelos, S.T. Ferreira, T.M. Carvalho, W. Souza, A.M. Kettlun, M. Mancilla, et al. (1996) Partial purification and immunohistochemical localization of ATP diphosphohydrolase from Schistosoma mansoni. Immunological cross-reactivities with potato apyrase and Toxoplasma gondii nucleoside triphosphate hydrolase. J Biol Chem 271(36), 22139-22145.
401. T.F. Wang, Y. Ou and G. Guidotti (1998) The transmembrane domains of ectoapyrase (CD39) affect its enzymatic activity and quaternary structure. J Biol Chem 273(38), 24814-24821.
402. Zhong X., Kriz R., Kumar R., Guidotti G. Distinctive roles of endoplasmic reticulum and golgi glycosylation in functional surface expression of mammalian E-NTPDase1, CD39. Biochim Biophys Acta. 2005.
403. H. Zimmermann, N. Braun, B. Kegel and P. Heine (1998) New insights into molecular structure and function of ectonucleotidases in the nervous system. Neurochem Int 32(5–6), 421-425.
404. B. Kegel, N. Braun, P. Heine, C.R. Maliszewski and H. Zimmermann (1997) An ecto-ATPase and an ecto-ATP diphosphohydrolase are expressed in rat brain. Neuropharmacology 36(9), 1189-1200.
405. K. Koziak, E. Kaczmarek, A. Kittel, J. Sevigny, J.K. Blusztajn, J. Schulte Am Esch II, et al. (2000) Palmitoylation targets CD39/endothelial ATP diphosphohydrolase to caveolae. J Biol Chem 275(3), 2057-2062.
406. S.C. Robson, E. Kaczmarek, J.B. Siegel, D. Candinas, K. Koziak, M. Millan, et al. (1997) Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 185(1), 153-163.
407. F. Krotz, H.Y. Sohn, M. Keller, T. Gloe, S.S. Bolz, B.F. Becker, et al. (2002) Depolarization of endothelial cells enhances platelet aggregation through oxidative inactivation of endothelial NTPDase. Arterioscler Thromb Vasc Biol 22(12), 2003-2009.
408. A. Kittel, E. Kaczmarek, J. Sevigny, K. Lengyel, E. Csizmadia and S.C. Robson (1999) CD39 as a caveolar-associated ectonucleotidase. Biochem Biophys Res Commun 262(3), 596-599.
409. Papanikolaou A., Papafotika A., Murphy C., Papamarcaki T., Tsolas O., Drab M., et al. Cholesterol-dependent lipid assemblies regulate the activity of the ecto-nucleotidase CD39. J Biol Chem. 2005.
410. A.J. Marcus, L.B. Safier, M.J. Broekman, N. Islam, J.H. Fliessbach, K.A. Hajjar, et al. (1995) Thrombosis and inflammation as multicellular processes: significance of cell–cell interactions. Thromb Haemost 74(1), 213-217.
411. A.J. Marcus, M.J. Broekman, J.H. Drosopoulos, D.J. Pinsky, N. Islam and C.R. Maliszewsk (2001) Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases. Ital Heart J 2(11), 824-830.
412. A. Marcus, M. Broekman, J. Drosopoulos, D. Pinsky, N. Islam, R. Gayle III, et al. (2001) Thromboregulation by endothelial cells: significance for occlusive vascular diseases. Arterioscler Thromb Vasc Biol 21(2), 178-182.
413. Y. Kawashima, T. Nagasawa and H. Ninomiya (2000) Contribution of ecto-5'-nucleotidase to the inhibition of platelet aggregation by human endothelial cells. Blood 96(6), 2157-2162.
414. Y.P. Cote, J.G. Filep, B. Battistini, J. Gauvreau, P. Sirois and A.R. Beaudoin (1992) Characterization of ATP-diphosphohydrolase activities in the intima and media of the bovine aorta: evidence for a regulatory role in platelet activation in vitro. Biochim Biophys Acta 1139(1–2), 133-142.
415. J. Linden (2001) Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41 775-787.
416. D. Yang, H. Chen, M. Koupenova, S.H. Carroll, A. Eliades, J.E. Freedman, et al. (2010) A new role for the A2b adenosine receptor in regulating platelet function. J Thromb Haemost 8(4), 817-827.
417. P. Koszalka, B. Ozuyaman, Y. Huo, A. Zernecke, U. Flogel, N. Braun, et al. (2004) Targeted disruption of cd73/ecto-5'-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res 95(8), 814-821.
418. C. Vial, B. Hechler, C. Leon, J.P. Cazenave and C. Gachet (1997) Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost 78(6), 1500-1504.
419. C. Leon, B. Hechler, C. Vial, C. Leray, J.P. Cazenave and C. Gachet (1997) The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 403(1), 26-30.
420. J.L. Daniel, C. Dangelmaier, J. Jin, B. Ashby, J.B. Smith and S.P. Kunapuli (1998) Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 273(4), 2024-2029.
421. C. Leon, C. Vial, J.P. Cazenave and C. Gachet (1996) Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor. Gene 171(2), 295-297.
422. S. Motte, D. Communi, S. Pirotton and J.M. Boeynaems (1995) Involvement of multiple receptors in the actions of extracellular ATP: the example of vascular endothelial cells. Int J Biochem Cell Biol 27(1), 1-7.
423. R. Fijnheer, M.N. Boomgaard, A.J. van den Eertwegh, C.H. Homburg, C.W. Gouwerok, H.A. Veldman, et al. (1992) Stored platelets release nucleotides as inhibitors of platelet function. Thromb Haemost 68(5), 595-599.
424. K. Enjyoji, J. Sevigny, Y. Lin, P.S. Frenette, P.D. Christie, J.S. Esch II, et al. (1999) Targeted disruption of CD39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 5(9), 1010-1017.
425. A. Kittel, Z.S. Csapo, E. Csizmadia, S.W. Jackson and S.C. Robson (2004) Co-localization of P2Y1 receptor and NTPDase1/CD39 within caveolae in human placenta. Eur J Histochem 48(3), 253-259.
426. J.M. Boeynaems and J.D. Pearson (1990) P2 purinoceptors on vascular endothelial cells: physiological significance and transduction mechanisms. Trends Pharmacol Sci 11(1), 34-37.
427. A. Coppola, L. Coppola, L dalla Mora, F.M. Limongelli, A. Grassia, L. Mastrolorenzo, et al. (2005) Vigorous exercise acutely changes platelet and B-lymphocyte CD39 expression. J Appl Physiol 98(4), 1414-1419.
428. R.B. Gayle III, C.R. Maliszewski, S.D. Gimpel, M.A. Schoenborn, R.G. Caspary, C. Richards, et al. (1998) Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39. J Clin Invest 101(9), 1851-1859.
429. D. Candinas, N. Koyamada, T. Miyatake, J. Siegel, W.W. Hancock, F.H. Bach, et al. (1996) Loss of rat glomerular ATP diphosphohydrolase activity during reperfusion injury is associated with oxidative stress reactions. Thromb Haemost 76(5), 807-812.
430. N. Koyamada, T. Miyatake, D. Candinas, P. Hechenleitner, J. Siegel, W.W. Hancock, et al. (1996) Apyrase administration prolongs discordant xenograft survival. Transplantation 62(12), 1739-1743.
431. S.C. Robson, Y. Wu, X. Sun, C. Knosalla, K. Dwyer and K. Enjyoji (2005) Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost 31(2), 217-233.
432. L. Belayev, L. Khoutorova, T.A. Deisher, A. Belayev, R. Busto, Y. Zhang, et al. (2003) Neuroprotective effect of SolCD39, a novel platelet aggregation inhibitor, on transient middle cerebral artery occlusion in rats. Stroke 34(3), 758-763.
433. A.J. Marcus, M.J. Broekman, J.H. Drosopoulos, N. Islam, D.J. Pinsky, C. Sesti, et al. (2003) Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases. J Pharmacol Exp Ther 305(1), 9-16.
434. K. Koziak, M. Bojakowska, S.C. Robson, K. Bojakowski, J. Soin, E. Csizmadia, et al. (2008) Overexpression of CD39/nucleoside triphosphate diphosphohydrolase-1 decreases smooth muscle cell proliferation and prevents neointima formation after angioplasty. J Thromb Haemost 6(7), 1191-1197.
435. D.J. Pinsky, M.J. Broekman, J.J. Peschon, K.L. Stocking, T. Fujita, R. Ramasamy, et al. (2002) Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 109(8), 1031-1040.
436. J.H. Drosopoulos, R. Kraemer, H. Shen, R.K. Upmacis, A.J. Marcus and E. Musi (2010) Human solCD39 inhibits injury-induced development of neointimal hyperplasia. Thromb Haemost 103(2), 426-434.
437. C.A. Haller, W. Cui, J. Wen, S.C. Robson and E.L. Chaikof (2006) Reconstitution of CD39 in liposomes amplifies nucleoside triphosphate diphosphohydrolase activity and restores thromboregulatory properties. J Vasc Surg 43(4), 816-823.
438. O. Guckelberger, X.F. Sun, J. Sevigny, M. Imai, E. Kaczmarek, K. Enjyoji, et al. (2004) Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Thromb Haemost 91(3), 576-586.
439. S.P. Gangadharan, M. Imai, K.K. Rhynhart, J. Sevigny, S.C. Robson and M.S. Conte (2001) Targeting platelet aggregation: CD39 gene transfer augments nucleoside triphosphate diphosphohydrolase activity in injured rabbit arteries. Surgery 130(2), 296-303.
440. S. Mazer, M. Fedarau, Y.-L. Liu, D.W. Huang, C.W. Towe, C.F. Liu, et al. (2004) Deletion of endothelial ectoapyrase (CD39) promotes atherogenesis in hyperlipidemic mice. American Heart Scientific Sessions, November
441. D.J. Friedman, M.E. Talbert, D.W. Bowden, B.I. Freedman, Y. Mukanya, K. Enjyoji, et al. (2009) Functional ENTPD1 polymorphisms in African Americans with diabetes and end-stage renal disease. Diabetes 58(4), 999-1006.
442. D.J. Friedman, B.M. Kunzli, Y.I. A-Rahim, J. Sevigny, P.O. Berberat, K. Enjyoji, et al. (2009) CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci USA 106(39), 16788-16793.
443. B.M. Kunzli, P.O. Berberat, K. Dwyer, S. Deaglio, E. Csizmadia, P. Cowan, et al. (2011) Variable impact of CD39 in experimental murine colitis. Dig Dis Sci 56(5), 1393-1403.
444. O. Poirier, C. Mao, C. Mallet, V. Nicaud, S.M. Herrmann, A. Evans, et al. (1999) Polymorphisms of the endothelial nitric oxide synthase gene—no consistent association with myocardial infarction in the ECTIM study. Eur J Clin Invest 29(4), 284-290.
445. N. Jeerooburkhan, L.C. Jones, S. Bujac, J.A. Cooper, G.J. Miller, P. Vallance, et al. (2001) Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease. Hypertension 38(5), 1054-1061.
446. B. Granath, R.R. Taylor, F.M. van Bockxmeer and C.D. Mamotte (2001) Lack of evidence for association between endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in the Australian Caucasian population. J Cardiovasc Risk 8(4), 235-241.
447. R. Alvarez, P. Gonzalez, A. Batalla, J.R. Reguero, G. Iglesias-Cubero, S. Hevia, et al. (2001) Association between the NOS3 (-786 T/C) and the ACE (I/D) DNA genotypes and early coronary artery disease. Nitric Oxide 5(4), 343-348.
448. G.P. Rossi, M. Cesari, M. Zanchetta, S. Colonna, G. Maiolino, L. Pedon, et al. (2003) The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol 41(6), 930-937.
449. G. Ghilardi, M.L. Biondi, M. DeMonti, M. Bernini, O. Turri, F. Massaro, et al. (2002) Independent risk factor for moderate to severe internal carotid artery stenosis: T786C mutation of the endothelial nitric oxide synthase gene. Clin Chem 48(7), 989-993.
450. K. Sharan, S. Surrey, S. Ballas, M. Borowski, M. Devoto, K.F. Wang, et al. (2004) Association of T-786C eNOS gene polymorphism with increased susceptibility to acute chest syndrome in females with sickle cell disease. Br J Haematol 124(2), 240-243.
451. M.E. Hyndman, H.G. Parsons, S. Verma, P.J. Bridge, S. Edworthy, C. Jones, et al. (2002) The T-786-->C mutation in endothelial nitric oxide synthase is associated with hypertension. Hypertension 39(4), 919-922.
452. J.J. Hwang, C.T. Tsai, H.M. Yeh, F.T. Chiang, K.L. Hsu, C.D. Tseng, et al. (2002) The 27-bp tandem repeat polymorphism in intron 4 of the endothelial nitric oxide synthase gene is not associated with coronary artery disease in a hospital-based Taiwanese population. Cardiology 97(2), 67-72.
453. N. Cine, A.C. Hatemi and N. Erginel-Unaltuna (2002) Association of a polymorphism of the ecNOS gene with myocardial infarction in a subgroup of Turkish MI patients. Clin Genet 61(1), 66-70.
454. A.V. Benjafield and B.J. Morris (2000) Association analyses of endothelial nitric oxide synthase gene polymorphisms in essential hypertension. Am J Hypertens 13(9), 994-998.
455. X.L. Wang, A.S. Sim, R.F. Badenhop, R.M. McCredie and D.E. Wilcken (1996) A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 2(1), 41-45.
456. M.S. Spence, P.G. McGlinchey, C.C. Patterson, A.R. Allen, G. Murphy, U. Bayraktutan, et al. (2004) Endothelial nitric oxide synthase gene polymorphism and ischemic heart disease. Am Heart J 148(5), 847-851.
457. C.Q. Jia, Y. Ning, T.T. Liu and Z.L. Liu (2005) Association between G894T mutation in endothelial nitric oxide synthase gene and premature coronary heart disease. Zhonghua Liu Xing Bing Xue Za Zhi 26(1), 51-53.
458. Y. Shimasaki, H. Yasue, M. Yoshimura, M. Nakayama, K. Kugiyama, H. Ogawa, et al. (1998) Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol 31(7), 1506-1510.
459. A.D. Hingorani, C.F. Liang, J. Fatibene, A. Lyon, S. Monteith, A. Parsons, et al. (1999) A common variant of the endothelial nitric oxide synthase (Glu298-->Asp) is a major risk factor for coronary artery disease in the UK. Circulation 100(14), 1515-1520.
460. G. Lembo, N. De Luca, C. Battagli, G. Iovino, A. Aretini, M. Musicco, et al. (2001) A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis. Stroke 32(3), 735-740.
461. K. Chang, S.H. Baek, K.B. Seung, P.J. Kim, S.H. Ihm, J.S. Chae, et al. (2003) The Glu298Asp polymorphism in the endothelial nitric oxide synthase gene is strongly associated with coronary spasm. Coron Artery Dis 14(4), 293-299.
462. B. Wolff, H.J. Grabe, C. Schluter, K. Popowski, H. Volzke, J. Ludemann, et al. (2005) Endothelial nitric oxide synthase Glu298Asp gene polymorphism, blood pressure and hypertension in a general population sample. J Hypertens 23(7), 1361-1366.
463. Y. Miyamoto, Y. Saito, N. Kajiyama, M. Yoshimura, Y. Shimasaki, M. Nakayama, et al. (1998) Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 32(1), 3-8.
464. T. Kishimoto, Y. Misawa, A. Kaetu, M. Nagai, Y. Osaki, M. Okamoto, et al. (2004) eNOS Glu298Asp polymorphism and hypertension in a cohort study in Japanese. Prev Med 39(5), 927-931.
465. P. Lacolley, S. Gautier, O. Poirier, B. Pannier, F. Cambien and A. Benetos (1998) Nitric oxide synthase gene polymorphisms, blood pressure and aortic stiffness in normotensive and hypertensive subjects. J Hypertens 16(1), 31-35.
466. A. Elbaz, O. Poirier, T. Moulin, F. Chedru, F. Cambien and P. Amarenco (2000) Association between the Glu298Asp polymorphism in the endothelial constitutive nitric oxide synthase gene and brain infarction. The GENIC Investigators. Stroke 31(7), 1634-1639.
467. K. Stangl, I. Cascorbi, M. Laule, T. Klein, V. Stangl, S. Rost, et al. (2000) High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics 10(2), 133-140.
468. A. Bonnardeaux, S. Nadaud, A. Charru, X. Jeunemaitre, P. Corvol and F. Soubrier (1995) Lack of evidence for linkage of the endothelial cell nitric oxide synthase gene to essential hypertension. Circulation 91(1), 96-102.
469. T. Nakayama, M. Soma, Y. Takahashi, Y. Izumi, K. Kanmatsuse and M. Esumi (1997) Association analysis of CA repeat polymorphism of the endothelial nitric oxide synthase gene with essential hypertension in Japanese. Clin Genet 51(1), 26-30.